Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Expanded access
- Sponsors Boehringer Ingelheim
- 09 Nov 2016 Status changed from recruiting to completed.
- 10 Sep 2014 New trial record